Tumba, Sweden

Chris Litten


Average Co-Inventor Count = 7.5

ph-index = 4

Forward Citations = 40(Granted Patents)


Location History:

  • Stubbestigen, SE (2006)
  • Tumba, SE (2006 - 2008)

Company Filing History:


Years Active: 2006-2008

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Chris Litten: Innovator in Thyroid-Related Medical Treatments

Introduction

Chris Litten, a dedicated inventor based in Tumba, Sweden, has made significant contributions to the field of medical science with a focus on thyroid receptor antagonism. With a total of five patents to his name, Litten's work has the potential to greatly impact the treatment of various cardiac and metabolic disorders.

Latest Patents

Among his latest patents, Litten has developed novel compounds that function as thyroid receptor ligands, specifically antagonists. These innovations aim to address conditions such as cardiac arrhythmias, thyrotoxicosis, and subclinical hyperthyroidism. One noteworthy patent outlines new thyroid receptor ligands characterized by a unique general formula, allowing for a range of applications in treating diseases associated with metabolic dysfunction. The conditions targeted include obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, and various thyroid-related diseases. His inventions not only pave the way for advanced therapeutic solutions but also provide an avenue for further research into metabolic health.

Career Highlights

Litten's career at Karo Bio AB has been marked by groundbreaking advancements in pharmaceutical science. His expertise in developing therapeutic compounds has been recognized within the industry, and his patents serve as testament to his innovative spirit and technical acumen.

Collaborations

Throughout his career, Chris Litten has collaborated with notable colleagues, including Johan Malm and Neeraj Garg. Together, they have pushed the boundaries of research and development in the field of thyroid medications, contributing to a deeper understanding and more effective treatment options for metabolic and cardiac disorders.

Conclusion

In conclusion, Chris Litten stands out as an influential inventor whose work continues to hold promise for improving the treatment landscape for individuals dealing with metabolic dysfunctions. His contributions to thyroid receptor antagonism and ongoing collaboration with fellow professionals illustrate a commitment to innovation and medical advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…